Adamis To Resubmit NDA For ZIMHI Within 45 Days - Quick Facts

Adamis Pharmaceuticals Corporation (ADMP) issued an update on the status of the NDA for ZIMHI high-dose naloxone injection product for the treatment of opioid overdose. The company had a Type A meeting with the FDA to review comments on the additional information provided by the company in response to the FDA's Complete Response Letter. Adamis said it believes the meeting was productive and plans to resubmit the NDA for ZIMHI to the FDA within the next 45 days.

Dennis Carlo, CEO of Adamis Pharmaceuticals, said: "We believe we obtained critical feedback from the FDA at our Type A meeting on a number of issues and also received an acknowledgement of the agency's intention to commit to a rapid review of the NDA."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Salt Lake City, Utah-based Creminelli Fine Meats is recalling around 4,207 pounds of ready-to-eat or RTE parmesan salami sticks citing misbranding and an undeclared allergen, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves 2.6-oz. plastic pouches containing "CREMINELLI FINE MEATS salami minis UNCURED ITALIAN SALAMI PARMESAN" with "BES The U.S. Food and Drug Administration is proposing a rule that will broaden the range of nonprescription or over-the counter drugs available to consumers. The rule titled, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use," is intended to increase options for the development of safe and effective nonprescription drugs. The U.S. Food and Drug Administration announced that Australian organic infant formula and baby food producer, Bellamy's Organic, has agreed to send around 696,000 cans of general formula milk to the United States to meet the supply shortage. Under the FDA's enforcement discretion to source more infant formula to the U.S., the available Bellamy's Organic products include about 1.4 million pounds.
Follow RTT